Navigation Links
Reportlinker Adds Successful Strategies for Drug Repositioning

NEW YORK, April 20, 2011 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Successful Strategies for Drug Repositioning


This report Highlights how drug repositioning can provide a low-risk approach to drug development. The success of the approach is illustrated by a number of case histories, mostly arising from serendipitous observations. The report illustrates systematic approaches to identify suitable opportunities that should lead to better success including those being pursued by specialist companies.

Features and benefits

* Analyze and understand the strategies employed in the most successful examples of drug repositioning.

* Discover the key technologies required to establish potential repositioning opportunities.

* Identify the specialist service providers with expertise in the key technologies required to systematically identify repositioning candidates.

* Discover how through repositioning a company can protect its intellectual property.

* Analyze the potential impact that drug repositioning can have on both large pharma companies and small specialist companies.


The pharma industry's revenue growth is low and it is failing to introduce sufficient new drugs to offset the impact of patent expirations despite record R&D costs. Repurposing of drugs offers a lower risk, lower cost, approach to new product development. Repurposing of development failures can recover what would otherwise be lost R&D expenditure.

The potential commercial benefits from successful repositioning of a drug are likely to be greater than those offered by simple reformulation, and offers opportunities for extended periods of market exclusivity via the granting of additional patents.

Major companies are well positioned to benefit from the successful repurposing of drugs, especially when they utilize both internal resources and external resources. The effective application of repurposing technologies should enable major companies to significantly enhance their development pipelines.

Your key questions answered

* What are the current advantages of repositioning over other lower risk approaches to drug development?

* What are the key technologies being used to identify new targets for molecules in companies' databases?

* How does drug repositioning improve the intellectual property position of companies that employ this strategy?

* What skills and platforms do specialist companies engaged in drug repositioning possess?

* How have molecules such as sildenafil and thalidomide been repositioned successfully?


Executive Summary

Chapter 1 Introduction

Chapter 2 Lower Risk Strategies

Chapter 3 What is Repositioning?

Chapter 4 Strategic Approaches to Repositioning

Chapter 5 Successful case studies

Chapter 6 Current Efforts

Chapter 7 Specialist Companies

Chapter 8 Outlook

About the author





The decline in approvals of novel chemical entities

The costs, and risks, of drug development

Lower Risk Strategies



Enantiomeric switches

Active metabolites



What is Repositioning?



Commercial implications

Intellectual property issues

Design or serendipity?

Strategic Approaches to Repositioning



Chemical space

New indications

Phenotypic approaches

Informatics-based approaches


Exploiting intellectual property

Increased licensing opportunities

Successful case studies







sildenafil (Viagra and Revatio)

Current Efforts



Major opportunities

Rare diseases

Drugs in advanced development

Inhaled formulations

Biological products

Modified formulations

Repurposing by combination

Other approaches

Specialist Companies



Almac Group

Ampio Pharmaceuticals

Anaxomics Biotech

APT Pharmaceuticals

Aureus Sciences



Cypress Bioscience


Horizon Discovery

Jenken Biosciences

Melior Discovery

NeuroHealing Pharmaceuticals




Ore Pharmaceutical Holdings

Radical Therapeutix

SOM Biotech

Somaxon Pharmaceuticals

Sosei Group

SWITCH Biotech

Tangent Reprofiling





Impact on major companies

Impact for specialist companies

Overall perspective




To order this report:

: Successful Strategies for Drug Repositioning

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg



US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Middle Eastern Medical Device Market: Facts and Figures2011
2. Reportlinker Adds Levosimendan - Comprehensive patent search
3. Reportlinker Adds Zolpidem - Key patent, SPC, and data exclusivity expiry (44 country coverage)
4. Reportlinker Adds North America Dental Devices Market Outlook to 2017
5. Reportlinker Adds ENT Devices Market Outlook in Brazil to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices
6. Reportlinker Adds ENT Devices Market Outlook in United States to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices
7. Reportlinker Adds Companion Diagnostics Partnering Terms and Agreements
8. Reportlinker Adds ENT Devices Market Outlook in China to 2017 - Hearing Aid Devices and Implants and Diagnostic Devices
9. Reportlinker Adds Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
10. Reportlinker Adds Neurology Devices Market Outlook in United States to 2017 - Neurostimulation Devices, Interventional Neurology and Others
11. Reportlinker Adds Arthritis Therapy Area Pipeline Report
Post Your Comments:
(Date:12/1/2015)... MARIETTA, Ga. , Dec. 1, 2015 ... purchase Dallas, Texas -based Tenet Healthcare,s ... WellStar Board of Trustees approved the strategic move following ... expand upon its proven clinical care models and patient ... improved access to healthcare to new communities. ...
(Date:12/1/2015)...  Eyeon Therapeutics has received a Notice of ... on a charged hydrophilic polymer developed at Particles ... has been shown to be safe and effective ... Mitchnick , MD, CEO states, "This second set ... in conjunction with a therapeutic agent.  Nanoparticles coated ...
(Date:12/1/2015)... Pharma Tech Outlook recently conducted a comprehensive ... Management Solution Providers - 2015 .  After careful consideration ... CIOs, VCs, analysts, and the Pharma Tech Outlook editorial ... 10 clinical data management solution providers (check out the ... 36 respectively). --> ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates mobile ... wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they are ... of North America (RSNA) 2015 annual meeting through December 3 in Chicago, Illinois, ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... that it has been selected as a finalist in this year’s Fierce Innovation ... FierceMobileHealthcare. Next IT Healthcare was recognized as a finalist in the category of ...
(Date:12/1/2015)... MA (PRWEB) , ... December 01, 2015 , ... Lutronic, ... release of Clarity, the latest addition to the devices for sale in the United ... 755 nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest ... Integration ,” addresses a main “pain point” for merging or aligning healthcare provider ... a deal is signed. This quick-read guidance suggests that failing to recognize ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , ... membership and leadership since 2008. Gary Bruce, President of PartnerTech North America, currently ... spent a significant amount of time in Sweden since joining PartnerTech based in ...
Breaking Medicine News(10 mins):